Physician profile
Donna H Moore
NPI 1073760864
$1,287.75
in general payments reported to CMS, 2019-2025
20 companies · $99.07 in 2025
The $99.07 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $613 · 2022: $340 · 2023: $162 · 2024: $73.10 · 2025: $99.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $191.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $177.35 | 2021-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.57 | 2021-2022 | |
| Lilly USA, LLC | $102.76 | 2021-2023 | Mounjaro, Trulicity |
| Novo Nordisk INC | $68.62 | 2022-2024 | Ozempic |
| Merck Sharp & Dohme LLC | $47.26 | 2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $40.40 | 2021-2022 | |
| Pfizer INC. | $39.86 | 2021 | |
| Dexcom, INC. | $34.74 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $34.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.34 | 2021 | |
| Amgen INC. | $27.56 | 2022 | |
| Averitas Pharma INC. | $27.11 | 2023 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2023 | Nuedexta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.79 | 2021 | |
| Seqirus USA INC | $18.48 | 2025 | Fluad, Flucelvax |
| Organogenesis INC. | $16.86 | 2024 | |
| Esperion Therapeutics, INC. | $12.40 | 2021 | |
| Amarin Pharma, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.